Heparan Sulfate Proteoglycans Mediate the Angiogenic Activity of the Vascular Endothelial Growth Factor Receptor-2 Agonist Gremlin

被引:63
|
作者
Chiodelli, Paola [1 ]
Mitola, Stefania [1 ]
Ravelli, Cosetta [1 ]
Oreste, Pasqua [2 ]
Rusnati, Marco [1 ]
Presta, Marco [1 ]
机构
[1] Univ Brescia, Unit Gen Pathol & Immunol, Dept Biomed Sci & Biotechnol, Sch Med, I-25123 Brescia, Italy
[2] Glycores, I-2000 Milan, Italy
关键词
angiogenesis; endothelium; gremlin; heparan sufate proteoglycans; ESCHERICHIA-COLI K5; BONE MORPHOGENETIC PROTEIN; POLYSACCHARIDE DERIVATIVES; FUNCTIONAL-CHARACTERIZATION; ANTAGONIST GREMLIN-1; STRUCTURAL FEATURES; FACTOR VEGF; HIV-1; TAT; CELLS; BINDING;
D O I
10.1161/ATVBAHA.111.235184
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective-Heparan sulfate proteoglycans (HSPGs) modulate the interaction of proangiogenic heparin-binding vascular endothelial growth factors (VEGFs) with signaling VEGF receptor-2 (VEGFR2) and neuropilin coreceptors in endothelial cells (ECs). The bone morphogenic protein antagonist gremlin is a proangiogenic ligand of VEGFR2, distinct from canonical VEGFs. Here we investigated the role of HSPGs in VEGFR2 interaction, signaling, and proangiogenic capacity of gremlin in ECs. Methods and Results-Surface plasmon resonance demonstrated that gremlin binds heparin and heparan sulfate, but not other glycosaminoglycans, via N-, 2-O, and 6-O-sulfated groups of the polysaccharide. Accordingly, gremlin binds HSPGs of the EC surface and extracellular matrix. Gremlin/HSPG interaction is prevented by free heparin and heparan sulfate digestion or undersulfation following EC treatment with heparinase II or sodium chlorate. However, at variance with canonical heparin-binding VEGFs, gremlin does not interact with neuropilin-1 coreceptor. On the other hand, HSPGs mediate VEGFR2 engagement and autophosphorylation, extracellular signaling-regulated kinase1/2 and p38 mitogen-activated protein kinase activation, and consequent proangiogenic responses of ECs to gremlin. On this basis, we evaluated the gremlin-antagonist activity of a panel of chemically sulfated derivatives of the Escherichia coli K5 polysaccharide. The results demonstrate that the highly N,O-sulfated derivative K5-N, OS(H) binds gremlin with high potency, thus inhibiting VEGFR2 interaction and angiogenic activity in vitro and in vivo. Conclusion-HSPGs act as functional gremlin coreceptors in ECs, affecting its productive interaction with VEGFR2 and angiogenic activity. This has allowed the identification of the biotechnological K5-N, OS(H) as a novel angiostatic gremlin antagonist. (Arterioscler Thromb Vasc Biol. 2011;31:e116-e127.)
引用
收藏
页码:E116 / E127
页数:12
相关论文
共 50 条
  • [41] Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis
    Shibuya, Masabumi
    JOURNAL OF BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2006, 39 (05): : 469 - 478
  • [42] Elevated Vascular Endothelial Growth Factor Receptor-2 Abundance Contributes to Increased Angiogenesis in Vascular Endothelial Growth Factor Receptor-1-Deficient Mice
    Ho, Vivienne C.
    Duan, Li-Juan
    Cronin, Chunxia
    Liang, Bruce T.
    Fong, Guo-Hua
    CIRCULATION, 2012, 126 (06) : 741 - +
  • [43] Vascular endothelial growth factor induces Shc association with vascular endothelial cadherin - A potential feedback mechanism to control vascular endothelial growth factor receptor-2 signaling
    Zanetti, A
    Lampugnani, MG
    Balconi, G
    Breviario, F
    Corada, M
    Lanfrancone, L
    Dejana, E
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (04) : 617 - 622
  • [44] Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2
    Molhoek, Kerrington R.
    Griesemann, Heinrich
    Shu, Jianfen
    Gershenwald, Jeffrey E.
    Brautigan, David L.
    Slingluff, Craig L., Jr.
    CANCER RESEARCH, 2008, 68 (11) : 4392 - 4397
  • [45] Clinical significance of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 gene polymorphisms in patients with gastrointestinal stromal tumors
    Kang, Byung Woog
    Kim, Jong Gwang
    Chae, Yee Soo
    Bae, Han Ik
    Kwon, Ohkyoung
    Chung, Ho Young
    Yu, Wansik
    Song, Hong Suk
    Kang, Yu Na
    Ryu, Seung Wan
    Lee, Kyung Hee
    Bae, Young Kyung
    Choi, Joon Hyuk
    Kim, Se Won
    Ryoo, Hun-Mo
    Cho, Chang-Ho
    Chae, Hyun-Dong
    Park, Kyun Woo
    Gu, Mi Jin
    Bae, Byung-Jo
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (02) : E40 - E45
  • [46] Differential ability of heparan sulfate proteoglycans to assemble the fibroblast growth factor receptor complex in situ
    Chang, Z
    Meyer, K
    Rapraeger, AC
    Friedl, A
    FASEB JOURNAL, 2000, 14 (01): : 137 - 144
  • [47] Expression and localization of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 in human epidermal appendages: a comparison study by immunofluorescence
    Man, X. -Y.
    Yang, X. -H.
    Cai, S. -Q.
    Bu, Z. -Y.
    Wu, X. -J.
    Lu, Z. -F.
    Zheng, M.
    CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2009, 34 (03) : 396 - 401
  • [48] Engineering a vascular endothelial growth factor 165-binding heparan sulfate for vascular therapy
    Wang, Chunming
    Poon, Selina
    Murali, Sadasivam
    Koo, Chuay-Yeng
    Bell, Tracey J.
    Hinkley, Simon F.
    Yeong, Huiqing
    Bhakoo, Kishore
    Nurcombe, Victor
    Cool, Simon M.
    BIOMATERIALS, 2014, 35 (25) : 6776 - 6786
  • [49] A critical requirement for heparan sulphate activation of vascular endothelial growth factor to mediate angiogenesis
    Hamilton, A.
    Bischof, H.
    Chen, L.
    Robinson, C. J.
    Yates, E. A.
    Turnbull, J. E.
    Mulloy, B.
    Stringer, S. E.
    INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, 2010, 91 (06) : A12 - A13
  • [50] Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity
    Alam, A
    Herault, JP
    Barron, P
    Favier, B
    Fons, P
    Delesque-Touchard, N
    Senegas, I
    Laboudie, P
    Bonnin, J
    Cassan, C
    Savi, P
    Ruggeri, B
    Carmeliet, P
    Bono, FO
    Herbert, JM
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 324 (02) : 909 - 915